Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.
Actively Recruiting
Researchers are evaluating the effectiveness of riliprubart compared to the usual treatment of intravenous immunoglobulin IVIg in adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP who are currently receiving maintenance IVIg therapy. This Phase 3 randomized study aims to understand how well riliprubart works in this group over a study duration of up to 109 weeks, including screening, treatment, and follow-up periods. Participants are randomly assigned to one of two groups one group receives riliprubart along with a placebo IVIg infusion for 24 weeks, followed by an open-label extension phase with riliprubart for another 24 weeks the other group continues IVIg treatment with a placebo riliprubart for 24 weeks, then also enters the open-label riliprubart extension. Treatments are given as intravenous or subcutaneous infusions, and dosing follows established maintenance regimens. During the study, participants will have regular assessments to monitor their response to treatment. These include measuring disability and fatigue scales, grip strength, and relapse rates from baseline through various time points up to week 109. Safety is monitored by tracking treatment-emergent adverse events and antibody development. Participants are followed closely through scheduled visits to evaluate changes in their condition and overall health status throughout the study.
Actively Recruiting
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
Actively Recruiting
Researchers are evaluating the long-term effectiveness and safety of drug-coated balloon DCB strategies, including DCB alone or combined with drug-eluting stents DES, compared to DES-only treatment in patients with chronic total occlusion CTO of coronary arteries after successful reopening. This multicenter randomized controlled trial aims to fill the gap in direct comparative data between DCB and DES treatments for CTO, with the goal of optimizing treatment strategies, reducing stent use, lowering complication risks, and improving patient outcomes. Participants will be randomly assigned to either the DCB group, which involves balloon angioplasty with drug coating and possible provisional DES implantation if needed hybrid strategy, or the DES-only group receiving standard drug-eluting stent placement. Both groups receive standard medical therapy including at least 12 months of dual antiplatelet therapy DAPT. The study includes a 9-month primary endpoint assessment and a 36-month follow-up period to monitor long-term outcomes. During the study, patients will undergo angiographic evaluation for late lumen loss at 9 months, assessed by an independent laboratory using quantitative coronary angiography. Clinical events such as target lesion failure, cardiac death, myocardial infarction, and repeat revascularization will be monitored up to 36 months. Patient-reported outcomes like angina status and quality of life, as well as intravascular imaging and safety parameters, will also be collected. Overall participation spans over three years with regular follow-up visits to assess treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety, tolerance, and preliminary effectiveness of LM-108 combined with anti-tumor treatments in people with advanced solid tumors. This multicenter, open-label Phase IbII clinical trial focuses on determining the best dose of LM-108 with penpulimab, oxaliplatin, and capecitabine in Phase Ib, and then assessing the combinations effects in Phase II. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive various drug combinations including LM-108 injection, penpulimab, oxaliplatin, capecitabine, and tislelizumab. These drugs are administered mainly via intravenous infusion on Day 1 of each 21-day treatment cycle, with capecitabine taken orally twice daily from Day 1 to Day 14 or with a specific dosing schedule. Different study groups receive different combinations and doses based on the trial phase and cohort. During the study, participants will be monitored for side effects and treatment responses through lab tests, imaging, and clinical evaluations. Key measurements include dose-limiting toxicities within 21 days of the first dose and progression-free survival over about 10 months. Other outcomes assessed are overall response rate, duration of response, disease control rate, overall survival up to 5 years, and safety events up to 90 days after the last dose. Participants will be followed regularly throughout the treatment cycles and monitored for immunogenicity and drug pharmacokinetics.
Actively Recruiting
Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.
Actively Recruiting
Researchers are evaluating ursodeoxycholic acid as a potential treatment for gastric intestinal metaplasia IM in adults who do not have Helicobacter pylori infection. This Phase 4 clinical trial aims to understand if ursodeoxycholic acid can help reverse IM and to assess any medical problems participants may experience while taking the medication. The study compares ursodeoxycholic acid to a placebo to determine its impact on this stomach condition. Participants are randomly assigned to one of two groups. One group takes oral ursodeoxycholic acid capsules at a dose of 250 mg three times daily for six months, while the other group takes matching placebo capsules at the same dose and schedule. Participants visit the clinic every four weeks for checkups, symptom evaluations, and to receive their medication supply. During the study, participants undergo assessments including upper gastrointestinal endoscopy and histopathological examinations to monitor changes in gastric intestinal metaplasia and gastric atrophy stages. Researchers measure the regression and progression rates of these conditions based on OLGIM and OLGA staging from enrollment through the six-month treatment period. Safety and any side effects are also closely monitored throughout the trial.
Actively Recruiting
Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, open-label study comparing two ways of giving the drug frexalimabby subcutaneous under the skin injection every 4 weeks versus intravenous IV infusion every 4 weeksin adults aged 18 to 60 years with relapsing multiple sclerosis RMS or non-relapsing secondary progressive multiple sclerosis nrSPMS. The study aims to evaluate the pharmacokinetics, safety, and efficacy of these two administration methods in this population. Participants will receive frexalimab either through an IV infusion or by subcutaneous injection using an on-body delivery system OBDS, with the option for home self-administration starting after appropriate training in Part B of the study. The treatment period for Parts A and B combined lasts 48 weeks 12 months, with an optional Part C continuing until a long-term safety study begins. Scheduled visits occur monthly between weeks 4 and 24, then every 1 to 3 months in Part B, and every 6 months in Part C. Participants discontinuing treatment early will have additional follow-up visits. During the study, participants will undergo regular on-site visits for drug administration and monitoring. Researchers will collect blood samples to assess drug levels and immune responses, perform MRI scans to track brain lesions, and monitor safety through adverse event reporting and laboratory tests. The studys main outcomes include drug concentration measurements up to week 24 and safety and efficacy assessments up to week 96. Follow-up after treatment ends will continue for 6 months to observe any ongoing effects.
Actively Recruiting
Researchers are conducting a multicenter, prospective observational study across 200 hospitals in China to examine current treatment patterns for chronic hepatitis B CHB. The study aims to compare patient outcomes under different treatment regimens to provide evidence-based data that can improve CHB treatment strategies and follow-up care, ultimately advancing efforts toward a functional cure for chronic hepatitis B. Participants include those receiving or planned to receive treatments such as entecavir ETV, tenofovir disoproxil fumarate TDF, tenofovir alafenamide fumarate TAF, tenofovir amibufenamide TMF, or peginterferon alpha-2b injection. The study observes real-world clinical practice without assigning treatments, capturing data on these therapies over an extended period. During the study, researchers will monitor outcomes including the percentage of patients developing HBsAg-associated hepatocellular carcinoma HCC, incidence of HCC, rates of HBsAg seroclearance and seroconversion, changes in HBsAg levels, HBV DNA levels, liver fibrosis improvement, and liver-related complications. Data collection spans from week 4 up to week 240, with continuous follow-up to assess treatment effects and patient status over time.
1-10 of 15
1